About Us
Nanophysics & Beyond
Curadigm
The Management
Our Commitments
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Investors
Corporate Presentation
Financial Calendar
Regulated Information
SEC Filings
Annual General Meetings
Shareholder Corner
Press Releases
Congresses & Events
Nanotalks
NBTXR3 Development
R&D Day
Our Expert Videos
Nanoblog
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Scientific Clinical | Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma
Scientific Clinical | Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S.
28 September 2017
Financial | Nanobiotix launches capital increase by means of an accelerated bookbuild offering
30 October 2017
Scientific Clinical | Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma
Published by
adminvl
on
23 October 2017
No translations available for this page
